If you are comparing Zepbound and Wegovy after menopause, the headline number is real but incomplete. In SURMOUNT-5, 751 adults with obesity but without diabetes lost an average of 20.2% of body weight with tirzepatide and 13.7% with injectable semaglutide at week 72. Waist change was 18.4 cm with tirzepatide and 13.0 cm with semaglutide. [1]
That is the strongest direct comparison so far. It does not answer every midlife question.
What did tirzepatide vs semaglutide show after menopause?
SURMOUNT-5 compared once-weekly tirzepatide at the maximum tolerated dose of 10 mg or 15 mg with once-weekly semaglutide at the maximum tolerated dose of 1.7 mg or 2.4 mg. Participants had obesity and did not have type 2 diabetes. Both groups also received lifestyle intervention. [1]
At 72 weeks, tirzepatide had the larger average effect on weight and waist size. More people in the tirzepatide group reached weight-loss thresholds of at least 10%, 15%, 20%, and 25%. The most common adverse events in both groups were gastrointestinal, usually mild to moderate, and occurred mainly during dose escalation. [1]
Both routes can be powerful. In this trial, tirzepatide moved the average result farther.
Why this is not just a menopause-weight question
Menopause can change fat distribution, sleep, symptoms, training tolerance, and metabolic risk. But SURMOUNT-5 was not designed to ask whether one medication is better specifically for perimenopausal or postmenopausal weight change.
That boundary matters because the cause of midlife weight gain is often mixed. Hot flashes can break sleep. Sleep loss can worsen appetite and glucose regulation. Joint pain can reduce activity. Some medications affect weight. Insulin resistance and polycystic ovary syndrome history can change the risk picture. A glucagon-like peptide-1 or dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 prescription may still fit, but the prescription should follow an intake, not replace it.
The existing oral semaglutide review covers the oral-pill question separately. Here, the focus is the injectable head-to-head evidence.
What semaglutide already proved against placebo
The semaglutide side of the comparison also has strong placebo-controlled evidence. In STEP 1, 1,961 adults with overweight or obesity and without diabetes received semaglutide 2.4 mg or placebo for 68 weeks with lifestyle intervention. Mean weight change was -14.9% with semaglutide and -2.4% with placebo. [2]
In that trial, 86.4% of semaglutide participants lost at least 5% of body weight, compared with 31.5% of placebo participants. A 15% loss occurred in 50.5% of semaglutide participants and 4.9% of placebo participants. [2]
That is why the right framing is not "semaglutide failed." It is "tirzepatide beat semaglutide in one open-label head-to-head obesity trial, while semaglutide still has strong evidence versus placebo."
What tirzepatide proved against placebo
The tirzepatide side also has its own placebo-controlled base. In SURMOUNT-1, 2,539 adults with body mass index 30 or higher, or body mass index 27 or higher with at least one weight-related complication, and without diabetes were assigned to tirzepatide 5 mg, 10 mg, 15 mg, or placebo for 72 weeks. Mean weight change was -15.0%, -19.5%, and -20.9% with the tirzepatide doses, compared with -3.1% with placebo. [5]
The 10 mg and 15 mg doses also produced a 20% or greater weight reduction in 50% and 57% of participants, compared with 3% on placebo. That matters because it shows the SURMOUNT-5 result did not appear in isolation. Tirzepatide already had strong obesity-trial evidence before the direct comparison with semaglutide. [5]
The limitation is the same limitation that matters across this cluster: these are obesity pharmacotherapy trials, not trials designed to isolate perimenopause, menopause, or postmenopause physiology. The result can inform a midlife intake. It cannot replace one.
Label boundaries that matter in a midlife intake
Zepbound is FDA-labeled to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least one weight-related condition. Its label also includes treatment of moderate to severe obstructive sleep apnea in adults with obesity. [3]
Wegovy is FDA-labeled for long-term weight management in adults with obesity or overweight with a weight-related condition, for adolescents with obesity, to reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and for noncirrhotic metabolic dysfunction-associated steatohepatitis with moderate to advanced fibrosis. [4]
Both labels include a thyroid C-cell tumor boxed warning and contraindications for a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. [3] [4] These are not casual wellness products. They are prescription medications that require clinical screening.
Decision matrix: stronger average result is not the whole choice
| Decision point | Tirzepatide may fit better when | Semaglutide may fit better when | Reason to pause either route |
|---|---|---|---|
| Main goal | The patient meets criteria and wants the strongest average weight-loss option shown in direct obesity-trial data | The patient meets criteria and prefers a glucagon-like peptide-1-only route with strong placebo-controlled data | The goal is cosmetic weight loss without a medical indication |
| Cardiometabolic context | Obesity, sleep apnea, insulin resistance, or weight-related conditions make a stronger average weight effect relevant | Established cardiovascular disease may make semaglutide's cardiovascular outcome evidence part of the discussion | Diabetes status, cardiovascular disease, kidney disease, or liver disease has not been reviewed |
| Tolerability | The patient understands dose escalation and can report persistent nausea, vomiting, reflux, constipation, or abdominal pain early | The patient has prior tirzepatide intolerance, access issues, or a reason to prefer semaglutide | Severe gastrointestinal symptoms, dehydration, or abdominal pain is already present |
| Midlife priorities | Weight loss is being paired with protein, resistance training, sleep care, and menopause symptom management | The same plan is in place and semaglutide is the better access, cost, or risk fit | There is no plan to protect lean mass, bone health, and nutrition |
| Maintenance | Long-term treatment, access, cost, and stopping scenarios are discussed up front | Long-term treatment, access, cost, and stopping scenarios are discussed up front | The plan ends at the first prescription without a follow-up strategy |
For a midlife woman, the useful answer is not "which one wins?" It is "which prescription path, if any, fits the medical indication, risk profile, maintenance reality, and menopause context?"
Red flags and reasons to pause either medication
| Red flag or pause point | Why it changes the decision |
|---|---|
| Personal or family history of medullary thyroid carcinoma or MEN 2 | Both labels list this as a contraindication. [3] [4] |
| Pregnancy, planned pregnancy, or no pregnancy-prevention plan when pregnancy is possible | Weight-management pharmacotherapy should not outrun reproductive-safety review. |
| Prior pancreatitis, active gallbladder disease, or severe persistent abdominal pain | These histories can change eligibility, monitoring, or the decision to use another route. |
| Vomiting, diarrhea, low fluid intake, diuretics, or kidney disease | Dehydration during dose escalation can raise kidney and electrolyte risk. |
| Current or recent eating disorder, severe appetite restriction, or rapid uncontrolled weight loss | Appetite-suppressing medication can worsen unsafe intake patterns. |
| Frailty, sarcopenia risk, low protein intake, or no resistance-training plan | Midlife weight loss without lean-mass protection can trade one health risk for another. |
These red flags do not mean every patient is excluded. They mean the medication choice belongs inside a real clinical assessment, with monitoring and a pause plan.
Maintenance is part of the drug choice
The maintenance question is not theoretical. In SURMOUNT-4, adults first received open-label tirzepatide for 36 weeks, then 670 participants were randomized to continue tirzepatide or switch to placebo for another 52 weeks. Participants had lost an average of 20.9% during the lead-in. From week 36 to week 88, the continued-tirzepatide group lost another 5.5%, while the placebo-switch group regained 14.0%. At week 88, 89.5% of those continuing tirzepatide maintained at least 80% of the lead-in weight loss, compared with 16.6% after switching to placebo. [6]
That finding is important for counseling because it makes "what happens if I stop?" part of the first visit, not a surprise later. A strong plan covers dose escalation, side-effect management, access interruptions, protein targets, resistance training, constipation and reflux prevention, sleep, menopause symptoms, and what threshold would trigger slowing, pausing, or switching therapy.
How to route the decision
| Intake finding | Why it changes the discussion |
|---|---|
| body mass index plus a weight-related condition | Determines whether prescription weight-management criteria may be met. |
| Severe hot flashes or broken sleep | Menopause symptom care may need to run alongside weight care. |
| Gallbladder, pancreatitis, thyroid cancer, MEN 2, or pregnancy history | May change eligibility or require a different route. |
| polycystic ovary syndrome, prediabetes, or insulin resistance history | Shifts the metabolic-risk conversation beyond the scale. |
| Prior glucagon-like peptide-1 intolerance | Makes dose escalation and side-effect planning more important than headline efficacy. |
| Interest in peptides | Requires separating peptide evidence limits from glucagon-like peptide-1 evidence. See the peptide therapy review. |
The practical point is also the clinical point. Do not promise menopause-specific weight loss from a trial that did not study menopause as the central question. It can say that tirzepatide has stronger average head-to-head weight-loss data than injectable semaglutide in adults with obesity without diabetes, and that a clinician can decide whether that evidence fits a midlife woman's medical situation.
What to ask a clinician
Ask:
- Do I meet labeled criteria for either medication?
- Which medication fits my history better: semaglutide, tirzepatide, another route, or no glucagon-like peptide-1 path right now?
- Do I have gallbladder, pancreatitis, thyroid cancer, MEN 2, pregnancy, eating-disorder, kidney, or medication factors that change the choice?
- How will we decide whether stronger average weight loss is worth the side-effect, cost, access, and maintenance tradeoffs?
- How will we protect muscle, protein intake, bone health, sleep, and menopause symptom control while weight changes?
- What would make us pause, switch, slow escalation, or stop?
The strongest comparison does not end with "pick the stronger drug." It ends with the screening questions that make either choice safer.
Bottom line
Tirzepatide has stronger average head-to-head weight-loss data than injectable semaglutide in adults with obesity without diabetes, but the right midlife choice is not the biggest average number alone. The better decision weighs label fit, contraindications, side effects, access, maintenance, muscle and bone protection, sleep, metabolic risk, and whether the evidence applies to this patient's goals. [1] [3] [4]
How the assessment helps
A structured assessment can organize body mass index criteria, weight-related conditions, prior glucagon-like peptide-1 response, diabetes status, gallbladder or pancreatitis history, kidney and hydration risk, side-effect tolerance, cost and access, protein and strength planning, and maintenance concerns so a clinician can decide whether tirzepatide, semaglutide, another route, or no prescription path fits. It is not a medication recommendation by itself.
Related reading:
- glucagon-like peptide-1 Eligibility After Menopause.
- Semaglutide After Menopause.
- Protein and Strength on glucagon-like peptide-1 medicines After Menopause.
References
[1] Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393(1):26-36. doi:10.1056/nejmoa2416394 https://pubmed.ncbi.nlm.nih.gov/40353578/
[2] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/nejmoa2032183 https://pubmed.ncbi.nlm.nih.gov/33567185/
[3] DailyMed. ZEPBOUND (tirzepatide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[4] DailyMed. WEGOVY (semaglutide) prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[5] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/nejmoa2206038 https://pubmed.ncbi.nlm.nih.gov/35658024/
[6] Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945 https://pubmed.ncbi.nlm.nih.gov/38078870/